Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page’s revision tag was updated to a newer version, indicating a small update to the study record’s metadata. This does not modify the study details or visible content.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now shows a new revision number (v3.6.3) replacing the previous v3.6.2, indicating a page update. This update does not alter study content or eligibility criteria.SummaryDifference0.0%

- Check40 days agoChange DetectedThe page revision tag changed from v3.6.0 to v3.6.2, signaling a newer build/version of the page. This reflects an update to the page infrastructure rather than alterations to study content.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page now displays 'No longer looking for participants' and standardizes the header to Intervention/Treatment, signaling that recruitment has closed. The page revision was updated to v3.6.0 and new help/navigation items (How to Read a Study Record, Common Questions, How to Join a Study) were added.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision tag updated from v3.5.4 to v3.5.5, reflecting a new release version displayed on the page. The update is administrative and does not change study data, eligibility criteria, or how users interact with the page.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page revision stamp changed from v3.5.3 to v3.5.4, indicating a small patch or metadata update rather than a substantive change to the page content.SummaryDifference0.0%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.